Pharos iBio Co., Ltd.

KOSDAQ:A388870 Stock Report

Market Cap: ₩96.3b

Pharos iBio Past Earnings Performance

Past criteria checks 0/6

Pharos iBio has been growing earnings at an average annual rate of 4.4%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 59.2% per year.

Key information

4.4%

Earnings growth rate

22.8%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-59.2%
Return on equity-52.6%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Not Too Worried About Pharos iBio's (KOSDAQ:388870) Cash Burn Situation

Dec 16
Here's Why We're Not Too Worried About Pharos iBio's (KOSDAQ:388870) Cash Burn Situation

We Think Pharos iBio (KOSDAQ:388870) Can Easily Afford To Drive Business Growth

Mar 07
We Think Pharos iBio (KOSDAQ:388870) Can Easily Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Pharos iBio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A388870 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-10,7133,1298,192
30 Jun 240-10,4933,3318,126
31 Mar 240-9,8093,3627,256
31 Dec 230-8,8583,2266,138
30 Sep 230-9,5403,2357,118
31 Mar 23300-15,1413,0307,021
31 Dec 22300-17,0622,9887,085
31 Dec 2157-31,4712,4595,544
31 Dec 20188-13,3981,4814,340
31 Dec 19421-4,9511,2581,587

Quality Earnings: A388870 is currently unprofitable.

Growing Profit Margin: A388870 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A388870 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare A388870's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A388870 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A388870 has a negative Return on Equity (-52.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:28
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharos iBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution